Zobrazeno 1 - 10
of 2 329
pro vyhledávání: ''
Autor:
Leila Zemoura, Damien Treguer, Nicolas Girard, Marie Brevet, A. Chapelier, Didier Decaudin, Olivier Deas, Sophie Chateau-Joubert, Stefano Cairo, Rania El Botty, Sergio Roman-Roman, André Nicolas, Didier Meseure, Ivan Bièche, Sophie Vacher, Ludmilla de Plater, Elodie Montaudon, Elisabetta Marangoni, Catherine Daniel, Fariba Nemati, Adnan Naguez, Alain Livartowski
Publikováno v:
Oncotarget. 12:859-872
Significant rational is available for specific targeting of PI3K/AKT/mTOR pathway in the treatment of non-small cell lung cancer (NSCLC). However, almost all clinical trials that have evaluated Pi3K pathway-based monotherapies/combinations did not ob
Autor:
José Manuel Mas, Carmen Montoto, Andrea Naves, Baldomero Oliva, Alonso Fernández-Nistal, Araceli López, Cristina Segú-Vergés, Enric Carcereny, Guillem Jorba, Mireia Coma
Publikováno v:
Oncotarget
Around 3–7% of patients with non-small cell lung cancer (NSCLC), which represent 85% of diagnosed lung cancers, have a rearrangement in the ALK gene that produces an abnormal activity of the ALK protein cell signaling pathway. The developed ALK tyr
Autor:
Ferdinando Riccardi, Bruno Chiurazzi, Raffaella Ruocco, Francesca Ambrosio, Maria Fiorella Brangi, Carmela Barbato, Vincenzo Di Lauro, Dario Arundine, M. Biglietto, Roberto Fiorentino, Francesco Jacopo Romano, Maresa Cammarota, Sarah Scagliarini, Livio Puglia, Ivana Cerillo, Carmen Mocerino
Publikováno v:
Oncotarget
The stock of therapeutic weapons available in metastatic colorectal cancer (mCRC) has been progressively grown over the years, with improving both survival and patients' clinical outcome: notwithstanding advances in the knowledge of mCRC biology, as
Publikováno v:
Oncotarget
Immunotherapy has been established as a standard of care for patients with malignant melanoma, however, the long-term side-effects of immunotherapy are still emerging. Studies over the last decade have documented increasing reports of endocrine dysfu
Autor:
Juliann E. Kosovec, Laila Babar, Shahin Ayazi, Gene Grant Finley, Ali H. Zaidi, Soyoung Lee, Blair A. Jobe, Ashten N. Omstead, Madison Salvitti, Ronan J. Kelly, Ping Zheng, Ajay Goel, Anastasia Gorbunova
Publikováno v:
Oncotarget
Background: Esophageal adenocarcinoma (EAC) is a deadly disease with limited treatment options. STING is a transmembrane protein that activates transcription of interferon genes, resulting in stimulation of APCs and enhanced CD8+ T-cell infiltration.
Autor:
Barry C. Johnson, Esther Mena, Nancy Moore, Cecilia Monge Bonilla, Frank I. Lin, Lamin Juwara, James H. Doroshow, Geraldine O'Sullivan Coyne, Matthew M. Ames, Matthew P. Goetz, Alice P. Chen, M. Liza Lindenberg, Larry Rubinstein, S. Kummar, Howard Streicher, Renee M. McGovern, Joseph M. Covey, Peter L. Choyke, Joel M. Reid, Richard Piekarz, Rachel Bishop, Naoko Takebe, Jerry M. Collins
Publikováno v:
Oncotarget
Background: Differential responses to tamoxifen may be due to inter-patient variability in tamoxifen metabolism into pharmacologically active Z-endoxifen. Z-endoxifen administration was anticipated to bypass these variations, increasing active drug l
Autor:
Yong Lu, Zheng Gang Zhang, Dilip Moonka, Yi Zhang, Mehdi Mohamad Zreik, Qingning Zeng, Michael Chopp, Louie Semaan, Mohamad Baqer Chamseddine
Publikováno v:
Oncotarget
Hepatocellular carcinoma (HCC) is the most common primary liver tumor worldwide. Current medical therapy for HCC has limited efficacy. The present study tests the hypothesis that human cerebral endothelial cell-derived exosomes carrying elevated miR-
Autor:
Karam Khaddour, Joshua Dowling, Jiayi Huang, Martha Council, David Chen, Lynn Cornelius, Tanner Johanns, Sonika Dahiya, George Ansstas
Publikováno v:
Oncotarget
Despite the substantial advances in the management of metastatic melanoma with the introduction of immune checkpoint inhibitors (ICI), many patients develop disease progression during treatment with immunotherapy. This has been suggested to be mediat
miR-708-5p enhances erlotinib/paclitaxel efficacy and overcomes chemoresistance in lung cancer cells
Autor:
Carol S. Lutz, Nicholas J. Monteleone
Publikováno v:
Oncotarget
Lung cancer is a collection of aggressive tumors generally not diagnosed until late-stage, resulting in high mortality rates. The vast majority of non-small cell lung cancer (NSCLC) patients undergo combinatory chemotherapeutic treatment, which initi
Publikováno v:
Oncotarget
Introduction: Endocrine therapy has played an important role in the management of ER positive breast cancer over recent decades. Despite this, not all patients respond equally to endocrine intervention, which can lead to resistance, associated diseas